McKinley Carter Wealth Services Inc. Has $262,000 Holdings in Pfizer Inc. (NYSE:PFE)

McKinley Carter Wealth Services Inc. lowered its stake in Pfizer Inc. (NYSE:PFE) by 16.9% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 9,892 shares of the biopharmaceutical company’s stock after selling 2,015 shares during the period. McKinley Carter Wealth Services Inc.’s holdings in Pfizer were worth $262,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. AQR Capital Management LLC raised its holdings in Pfizer by 1.6% during the second quarter. AQR Capital Management LLC now owns 612,429 shares of the biopharmaceutical company’s stock worth $17,068,000 after acquiring an additional 9,435 shares in the last quarter. Quarry LP bought a new stake in shares of Pfizer during the second quarter worth approximately $31,000. Dana Investment Advisors Inc. grew its holdings in Pfizer by 9.6% in the 2nd quarter. Dana Investment Advisors Inc. now owns 100,181 shares of the biopharmaceutical company’s stock valued at $2,803,000 after buying an additional 8,771 shares in the last quarter. Souders Financial Advisors grew its position in shares of Pfizer by 6.1% during the 2nd quarter. Souders Financial Advisors now owns 8,347 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 483 shares in the last quarter. Finally, Birmingham Capital Management Co. Inc. AL increased its position in shares of Pfizer by 0.9% in the second quarter. Birmingham Capital Management Co. Inc. AL now owns 181,763 shares of the biopharmaceutical company’s stock worth $5,086,000 after purchasing an additional 1,559 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Trading Down 0.4 %

Shares of PFE stock opened at $26.65 on Thursday. The company has a 50-day simple moving average of $26.18 and a two-hundred day simple moving average of $27.91. The company has a market capitalization of $151.00 billion, a price-to-earnings ratio of 36.01, a PEG ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a 52-week low of $24.48 and a 52-week high of $31.54. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The firm had revenue of $17.70 billion for the quarter, compared to analysts’ expectations of $14.92 billion. During the same period in the previous year, the company earned ($0.17) earnings per share. The company’s quarterly revenue was up 31.2% on a year-over-year basis. Research analysts anticipate that Pfizer Inc. will post 2.94 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be paid a dividend of $0.43 per share. This is an increase from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 annualized dividend and a dividend yield of 6.46%. Pfizer’s dividend payout ratio is presently 227.03%.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on PFE. Truist Financial decreased their target price on Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Wolfe Research assumed coverage on Pfizer in a research report on Friday, November 15th. They set an “underperform” rating and a $25.00 target price for the company. Guggenheim dropped their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $45.00 price target on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.